BCTX BriaCell Therapeutics Corp.: Bathi resik saben saham sajrone 12 wulan pungkasan

Logo perusahaan publik BriaCell Therapeutics Corp (BCTX)

BriaCell Therapeutics (BCTX) management is scaling clinical trials, which is temporarily increasing current expenditures. The trailing twelve months (ttm) net income per share growth rate visualizes the results of this strategy, where 88.10 shows the value of this parameter. Oncology experts ensure process transparency for investors, while innovative developments in the US and Canada create a foundation for the fight against breast cancer.

BriaCell Therapeutics Corp. (BCTX): Bathi saben saham sajrone rolas wulan pungkasan saka 11.02.2024 nganti 17.11.2026

BCTX (BriaCell Therapeutics): rincian analitis lan laporan miturut indikator

Pambiji fundamental perusahaan:BCTX (BriaCell)
Barang unggulan BriaCell Corp

When constructing a long-term portfolio, asset screening requires an analysis of earnings resilience amid liquidity contraction and high Fed rates. This indicator measures the percentage change in net income per share over the last twelve months, reflecting the efficiency of BriaCell Therapeutics (BCTX) in capitalizing on innovations in personalized cancer immunotherapy via the annual EPS TTM delta.